Objective: There is much evidence for the detrimental effect of treatment interruptions on tumor control, particularly in head and neck cancer. In order to determine the outcome of the treatment interruptions in postoperative irradiation of breast cancer, 853 female patients treated between 1990 and 1999 inclusive were retrospectively analyzed. Methods: Locally advanced breast cancer patients who received neoadjuvant chemotherapy were not included in the study. Five hundred and forty-six patients (64%) treated with mastectomy and 307 patients (36%) with breast-conserving surgery were analyzed. A total dose of 50 Gy (46–54 Gy) was given to the chest wall/breast and regional lymph nodes in 1.8- to 2-Gy daily fractions, 5 times per week. A 14-Gy (10- to 20-Gy) photon or electron boost was given to the tumor bed of the patients with breast-conserving surgery. Unplanned treatment interruptions occurred in 741 (87%) of the patients and the median duration of the gaps was 13 days (1–91 days). A total of 348 patients (41%) had no treatment break or interruptions of 1 week or less, whereas 505 patients (59%) had treatment interruptions of more than 1 week. The locoregional control (LC) and overall survival (OS) rates were estimated with the Kaplan-Meier method. A Cox proportional hazard regression model was used to evaluate the influence of host- and treatment-related factors on LC and OS (age, menopausal status, histological subtype, grade, hormonal receptor status, pT stage, pN stage, type of surgery, adjuvant treatment, number of gaps and duration of gaps). Results: For all patients LC rates for 5 and 10 years were 95 and 87%, respectively, and OS rates were 78% for 5 years and 62% for 10 years. LC rates for the group of patients with no treatment break or interruptions of 1 week or less, for 5 and 10 years were 94 and 90%, whereas the LC rates for 5 and 10 years were 89 and 86%, for the group of patients with interruptions of more than 1 week (p = 0.019). Treatment interruptions of more than 1 week and premenopausal status appeared to be independent adverse prognostic factors in multivariate analyses affecting the LC (p = 0.043 and p = 0.005, respectively). The OS rates for the patients without treatment interruptions or interruptions of 1 week or less were also significantly better than for the patients with treatment interruptions of more than 1 week (p = 0.026) in multivariate analyses. Conclusion: Interruptions more than 1 week during postoperative irradiation of breast cancer adversely affect the treatment outcome.

Keywords:
Breast cancer, Radiotherapy, postoperative, Treatment interruption, Treatment time, overall, Treatment, prolonged, Treatment delay, Breast cancer, local control, Breast cancer, overall survival
1.
Macijewski B, Preuss-Bayer G, Trott KR: The influence of the number of fractions and overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys1983;9:321–328.
2.
Maciejewski B, Withers HR, Taylor JMG, Hliniak A: Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989;16:831–843.
3.
Barton MB, Keane TJ, Gadalla T, Maki E: The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol 1992;23:137–143.
4.
Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM: The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997;39:703–710.
5.
Robertson C, Robertson G, Hendry JH, Roberts SA, Slevin NJ, Duncan WB, MacDougall RH, Kerr GR, O’Sullivan B, Keane TJ: Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys1998;40:319–329.
6.
Coles CE, Burgress L, Tan T: An audit of delays before and during radical radiotherapy for cervical cancer-effect on tumour cure probability. Clin Oncol 2003;15:47–54.
7.
Videtic GMM, Fung K, Tomiak AT, et al: Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 2001;33:249–258.
8.
Weber DC, Kurtz JM, Allal AS: The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001;50:675–680.
9.
Suwinski R, Sowa A, Rutkowski T, Wydamanski J, Tarnawski R, Maciejewski B: Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys2003;56:399–412.
10.
Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys2000;46:269–279.
11.
Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ: Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003;21:555–563.
12.
Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356–1361.
13.
American Joint Committee on Cancer: Handbook for Staging of Cancer, from the Manual for Staging Cancer, ed 4. Philadelphia, Lippincott, 1993.
14.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc B 1958;53:457–481.
15.
Cox DR: Regression models and life-tables (with discussion). JR Stat Soc B 1972;34:187–220.
16.
Vikram B, Mishra UB, Strong EW,Manolatos S: Patterns of failure in carcinoma of the nasopharynx. I. Failure at the primary site. Int J Radiat Oncol Biol Phys 1985;11:1455–1459.
17.
Amdur RJ, Parsons JT, Mendhall WM, et al: Split-course versus continuous course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1989;17:279–285.
18.
Skladowski K, Law MG, Maciejewski B, Steel GG: Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol 1994;30:109–120.
19.
Steene JV, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival. Radiother Oncol 2000;55:263–272.
20.
Early Breast Cancer Trialists’ Collaborative Group: Favorable and unfavorable effects on long term survival of radiotherapy for early breast cancer. Lancet 2000;355:1757–1770.
21.
Carlson RW, Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, Masetti R, Schwartsmann G: Treatment of breast cancer in countries with limited resources. Breast J 2003;9(suppl 2):67–74.
22.
Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, WolffA; National Comprehensive Cancer Network: NCCN Practice Guidelines for Breast Cancer. Oncology2000;14:33–49.
23.
Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW Jr, Whelan TJ, Pfister DG: Post-mastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569.
24.
Bese NS, Öber A, Okkan S: Retrospective analysis of breast cancer patients treated with post-mastectomy radiation therapy and evaluation of prognostic factors for locoregional control and survival. J BUON 2001;6:255–261.
25.
Steel GG: Growth Kinetics of Human Tumors. Oxford, Clarendon Press, 1977, pp 40–52.
26.
Johnson AE, Bennett MH, Cheung CWD, et al: The management of individual breast cancers. Breast 1995;4:100–111.
27.
Johnson AE, Shekhdar J: Interval cancers in the NHS breast screening programme. Br J Radiol 1995;68:862–869.
28.
Fowler JF: Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumour treatment – continually rapid proliferation unmasked. Radiother Oncol 1991;22:156–158.
29.
Orton C, Ellis F: A simplification in the use of NSD concept in practical radiotherapy. Br J Radiol 1973;46:529.
30.
Ellis F: Dose, time and fractionation: a clinical hypothesis. Clin Radiol 1969;20:1.
31.
Kirk J, Gray W, Watson R: Cumulative radiation effect. I. Fractionated treatment regimes. Clin Radiol 1971;22:145.
32.
Sinclair JA, Oates JP, Dale RG: Bed-time charts and their application to the problems of interruptions in external beam radiotherapy treatments. Int J Radiat Oncol Biol Phys 1999;44:381–389.
33.
Dale RG, Hendry JH, Jones B, Robertson AG, Deehan C, Sinclair JA: Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules. Clin Oncol 2002;15:382–393.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.